PSUSA/00001317/202503
Submitted by Anonymous (not verified) on 5 November 2025 - 16:22
PSUSA/00001317/202503
PSUSA/00001466/202503
Submitted by Anonymous (not verified) on 5 November 2025 - 16:05
PSUSA/00001466/202503
Veterinary medicines European public assessment report (EPAR): Portela, relfovetmab, Status: Authorised
Submitted by Anonymous (not verified) on 5 November 2025 - 14:54
Veterinary medicines European public assessment report (EPAR): Portela, relfovetmab, Status: Authorised
On-boarding of users to Substance, Product, Organisation and Referentials (SPOR) data services
Submitted by Anonymous (not verified) on 5 November 2025 - 14:00
On-boarding of users to Substance, Product, Organisation and Referentials (SPOR) data services
Human medicines European public assessment report (EPAR): Ivemend, fosaprepitant, Date of authorisation: 11/01/2008, Revision: 27, Status: Authorised
Submitted by Anonymous (not verified) on 5 November 2025 - 13:55
Human medicines European public assessment report (EPAR): Ivemend, fosaprepitant, Date of authorisation: 11/01/2008, Revision: 27, Status: Authorised
European Medicines Agency Write PMS API implementation Guide
Submitted by Anonymous (not verified) on 5 November 2025 - 13:45
European Medicines Agency Write PMS API implementation Guide
Guidelines Consistency Group
Submitted by Anonymous (not verified) on 5 November 2025 - 13:37
Guidelines Consistency Group
Applications for new human medicines under evaluation: November 2025
Submitted by Anonymous (not verified) on 5 November 2025 - 13:32
Applications for new human medicines under evaluation: November 2025
Minutes - PDCO minutes of the 9-12 September 2025 meeting
Submitted by Anonymous (not verified) on 5 November 2025 - 13:04
Minutes - PDCO minutes of the 9-12 September 2025 meeting
Human medicines European public assessment report (EPAR): Rekambys, rilpivirine, Date of authorisation: 17/12/2020, Revision: 13, Status: Authorised
Submitted by Anonymous (not verified) on 4 November 2025 - 16:15
Human medicines European public assessment report (EPAR): Rekambys, rilpivirine, Date of authorisation: 17/12/2020, Revision: 13, Status: Authorised